Long-term healthcare resource utilisation and costs before and after initiation of risperidone treatment in patients with chronic schizophrenia

Clinical Drug Investigation

Volumn 18, Issue 3, 1999, Pages 233-237

  Keegan, David L ^a,c   Albright, Penny ^b   Petersen, Trish ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Janssen Ortho Inc   (Canada)

^c Saskatoon City Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; RISPERIDONE; SEDATIVE AGENT;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG COST; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH SERVICE; PRIORITY JOURNAL; QUALITY OF LIFE; RESOURCE ALLOCATION; SCHIZOPHRENIA;

EID: 0032851492     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199918030-00008     Document Type: Article

References (20)

1. 1. Revicki DA, Luce BR, Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 1995; 31: 57-65
2. 2. Revicki DA, Murray M, Assessing health-related quality of life outcomes of drug treatments for psychiatric disorders, CNS Drugs 1994; 1: 465-76
3. 3. Wasylenki DA. The cost of schizophrenia. Can J Psychiatry 1994; 39 (9 Suppl. 2): S65-9
4. 4. Williams R, Dickson RA. Economics of schizophrenia. Can J Psychiatry 1995; 40 (7 Suppl. 2): S60-7
5. 5. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162: 38-42
6. 6. Albright P, Livingstone S, Keegan D, et al. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: a retrospective analysis using the Saskatchewan Health Linkahle Databases. Clin Drug Invest 1996; 11: 289-99
7. 7. Keegan D. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug. Can J Psychiatry 1994; 39 (9 Suppl. 2): S46-52
8. 8. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-40
9. 9. Remington GJ. Clinical consideration in the use of risperidone. Can J Psychiatry 1993; 38 Suppl. 3: S96-100
10. 10. Marder SR, Meiback RC, Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35
11. 11. Revicki DA. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J Psychiatry Neurosci 1997; 22: 256-66
12. 12. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996; 57 Suppl. 9: 66-76
13. 13. Reid WH, Mason M, Toprac M. Savings in hospital bed-days related to treatment with clozapine. Hosp Community Psychiatry 1994; 45: 261-4
14. 14. Honigfeld G, Putin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Community Psychiatry 1990; 41I: 882-5
15. 15. Jonsson D, Walinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 1995; 92: 199-201
16. 16. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150: 1630-8
17. 17. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993; 15: 917-26
18. 18. Viale G, Meehling L, Maislin G, et al. Impact of risperidone on the use of mental health care resources. Psychiatr Serv 1997; 48: 1153-9
19. 19. Rawson NS, Malcolm E, D'Arcy C. Reliability of the recording of schizophrenia and depressive disorder in the Saskatchewan Health Care Datafiles. Soc Psychiatry Psychiatr Epidemiol 1997; 32: 191-9
20. 20. Glennie JL. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Technology overview: Pharmaceuticals. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1997 July